ALLR
Allarity Therapeutics, Inc.
Next earnings Aug 15, 2026 · consensus $-0.26 EPS
$1.30
▲ +2.36%$1.30▲ +30.00%
over 1Y
L $0.81EODHDH $1.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.4%
1W+2.4%
1M-24.9%
3M+21.5%
YTD+14.0%
1Y+30.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.86x); but unprofitable (net margin -3509.7%).
Revenue (FY2025) $320K · FY2025
Allarity Therapeutics, Inc. shows $320K in FY2025 revenue, a -3509.7% net margin, and -114.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $320K |
| Gross profit | — | -$2.27M | — | — | — |
| Operating income | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M |
| Net income | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
| Diluted EPS | -$4.19 | -$3,093.42 | -$10.26 | — | — |
| Net margin | — | — | — | — | -3509.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$8.81M
EV / EBITDA—
EV / Sales27.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-54.6%
FCF yield-72.1%
Quality & risk
ROIC (est.)-78.0%
Free cash flow-$14.8M
Total debt$2.94M
Net cash$11.8M
Altman Z-Score-10.16 distress
Piotroski F-Score4/8
Capital returns
Buyback yield15.5%
Dividend yield (est.)—
Shareholder yield15.5%
Shares Δ YoY-7.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-05-272026-06-02open ↗10-QPeriod ending 2026-03-312026-05-15open ↗4Period ending 2026-01-282026-05-14open ↗4Period ending 2026-01-282026-05-11open ↗3Period ending 2025-06-102026-05-11open ↗8-KPeriod ending 2026-05-082026-05-08open ↗4Period ending 2026-01-282026-05-07open ↗8-KPeriod ending 2026-05-052026-05-06open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEFA14AFiling2026-04-30open ↗DEF 14APeriod ending 2026-06-262026-04-30open ↗
Frequently asked
- Is Allarity Therapeutics, Inc. (ALLR) a buy?
- ALLR currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.86x); but unprofitable (net margin -3509.7%).
- What is Allarity Therapeutics, Inc.'s quality score?
- ALLR scores 47.94117647058823/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001860657, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 7:40:04 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.